Headquartered in Aachen, Germany, the company was established in 1946 and has grown to become a leader in research, development, and commercialization of treatments for pain and other diseases with high unmet medical needs.

Grünenthal specializes in developing innovative therapies for pain management, with a focus on neuropathic pain, chronic pain conditions, and acute pain treatment. Its robust portfolio includes both prescription medications and non-prescription products, with a strong emphasis on advancing research and patient-centric solutions. The company is also actively engaged in partnerships with healthcare professionals, scientific organizations, and other stakeholders to enhance therapeutic options and outcomes.

The company is dedicated to fostering innovation, reflected in its significant investments in research and development. Grünenthal maintains a presence in over 30 countries, with products available in more than 100 markets worldwide. Its state-of-the-art R&D facilities and collaborations with academic institutions ensure the continuous exploration of new treatment modalities.